Qube Research & Technologies Ltd Grows Stock Position in Celgene Co. (NASDAQ:CELG)

Share on StockTwits

Qube Research & Technologies Ltd grew its holdings in shares of Celgene Co. (NASDAQ:CELG) by 43.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,914 shares of the biopharmaceutical company’s stock after purchasing an additional 3,922 shares during the quarter. Qube Research & Technologies Ltd’s holdings in Celgene were worth $1,194,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its position in shares of Celgene by 89.3% during the 1st quarter. FMR LLC now owns 16,656,629 shares of the biopharmaceutical company’s stock valued at $1,571,387,000 after purchasing an additional 7,856,422 shares during the last quarter. Geode Capital Management LLC increased its holdings in Celgene by 8.6% in the 4th quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock worth $636,179,000 after acquiring an additional 787,638 shares in the last quarter. Abrams Capital Management L.P. purchased a new stake in Celgene in the 1st quarter worth approximately $637,066,000. American Century Companies Inc. increased its holdings in Celgene by 4.7% in the 1st quarter. American Century Companies Inc. now owns 3,865,722 shares of the biopharmaceutical company’s stock worth $364,692,000 after acquiring an additional 172,466 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Celgene by 1.0% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,990,147 shares of the biopharmaceutical company’s stock worth $282,090,000 after acquiring an additional 28,374 shares in the last quarter. 74.19% of the stock is owned by hedge funds and other institutional investors.

CELG stock traded up $1.43 during midday trading on Friday, hitting $94.74. The company’s stock had a trading volume of 2,572,000 shares, compared to its average volume of 3,866,949. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $98.97. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $66.13 billion, a price-to-earnings ratio of 12.45, a price-to-earnings-growth ratio of 0.44 and a beta of 1.46. The company has a 50 day moving average of $92.80 and a two-hundred day moving average of $92.51.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The business had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.22 billion. During the same period in the prior year, the company posted $2.16 EPS. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. On average, analysts anticipate that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the stock. Mizuho reissued a “buy” rating and issued a $103.00 target price on shares of Celgene in a report on Wednesday, July 3rd. ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Cowen reissued a “hold” rating and issued a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a report on Tuesday, July 23rd. Finally, Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price for the company. in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $94.81.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Google Finance Portfolio

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.